All Updates

All Updates

icon
Filter
Partnerships
Alex Therapeutics partners with Navamedic to develop Parkinson's disease companion app
Preventive Healthcare
Sep 12, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Sep 12, 2024

Alex Therapeutics partners with Navamedic to develop Parkinson's disease companion app

Partnerships

  • Alex Therapeutics, a digital health provider, and Navamedic, a Sweden-based pharmaceutical company, have partnered to develop a companion app for managing Parkinson's disease treatment.

  • The app will provide medication management assistance to patients using Flexilev, a prescription treatment for Parkinson's disease. It will complement the OraFID dose dispenser, offering a unique combination to help patients adhere to precise and individualized treatment regimens. Further, it is set to launch in Sweden, Norway, and Denmark in the coming year, with plans for further global expansion.

  • Analyst QuickTake: In January 2022 , the company partnered with Pfizer to develop a digital therapeutics (DTx) app to treat nicotine addiction. The company had also partnered with Vicore Pharma to develop a DTx for treating anxiety and depression in patients with idiopathic pulmonary fibrosis.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.